News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Dermapharm confirms stable business development in H1 2025 and records EBITDA growth in Q2 versus prior-year quarter
Dermapharm confirms stable business development in H1 2025 with EBITDA growth in Q2. Full-year guidance for 2025 reiterated. Branded pharmaceuticals main growth driver -
-
-
-